Large study tests new drug combinations for advanced cervical cancer
NCT ID NCT07266350
Summary
This study aims to observe the safety and effectiveness of treatments involving the drugs camrelizumab or famitinib for women with recurrent or metastatic cervical cancer. It will follow about 1,300 patients who have already decided to receive one of these treatments as part of their regular care. The main goal is to see how well these treatments work and what side effects patients experience in real-world settings.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER RECURRENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.